Drug Profile

Efgivanermin alfa - AstraZeneca

Alternative Names: MEDI1873

Latest Information Update: 26 Feb 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MedImmune
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Immunomodulators; TNFRSF18 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Solid tumours

Most Recent Events

14 Feb 2019 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease) in USA (IV) (AstraZeneca pipeline, February 2019)
28 Jan 2019 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (IV)
08 Jan 2019 MedImmune completes a phase I trial in Solid tumours (Metastatic disease, Late stage disease) in USA (IV) (NCT02583165)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com